A Random, Double-Blind, Multicenter, Positive Control and Placebo Control Phase Two Trail to Evaluate the Safety and Immunogenicity of Live Attenuated Influenza Vaccine in 3-59y Healthy People
Latest Information Update: 07 Mar 2024
At a glance
- Drugs Influenza vaccine live attenuated (Nasovac-S) (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Changchun BCHT Biotechnology
- 21 Mar 2022 New trial record